Hyperlipidemia Drugs Market (2020-2025): Global Trends, Demand, Opportunity and Future Forecast

Global Hyperlipidemia Drugs Market Research Report and Forecast 2020 - 2025

www.imarcgroup.com

Sales@imarcgroup.com

+1-631-791-1145

About IMARC

WHO WE ARE? • We are a leading market research firm with expertise in market intelligence and business research • We deliver high quality, well-knitted, meaningful studies • We excel at understanding and synergizing with the business priorities of our partners and delivering tailored solutions

WHAT DO WE DO? • Market research and business insights • Competitive intelligence and benchmarking • Strategy consulting • Consumer surveys and feedback analysis

WHAT DO WE COVER? • Food And beverages • Dairy and dairy products • Agriculture and farming • Chemicals and materials • FMCG • Paper and packaging

• Social and rural research

• Healthcare

• Market entry strategy

• Machinery, electronics and semiconductors

• Syndicated Reports

WHO DO WE SERVE? • Collaborating with fortune 500 companies and SMEs • Serving all major clients from different industry which include Chemical & Materials, Food & Beverages, Packaging, Healthcare, Automotive, Heavy Industries, Retail, etc.

WhatWe Do

Competitive Intelligence and Benchmarking At IMARC, we help customers determine a competitor’s brand image and perception in the marketplace as compared to other key players.

Cost Modeling and Cost Forecasting A good cost model supports organizations during negotiations to build strong relationships with suppliers. Cost modelling and price forecasting services from IMARC ensure clients make informed decisions.

Market Research & Business Insights To develop deep customer understanding, we employ a range of quantitative and qualitative marketing research approaches along with big data techniques that are both innovative and pragmatic

Country Entry Strategy IMARC team drafts and implement an optimum country entry strategy for expanding business in the country. Our team of consultants deeply evaluates and strategize the market opportunities for our clients and accentuate the business in congruence with Government regulations, exports and imports scenario, demand supply gap analysis and many more.

Consumer Survey & Feedback Reports Consumer profiling, survey with end consumers, collection of their feedback and deep analysis. Based on the analysis, strategic decisions to enter in a new region, launch of new product, improvising the existing services

Competitive Intelligence and Benchmarking

Market Research & Business Insights

Consumer Survey & Feedback Reports

Country Entry Strategy

Cost Modeling and Cost Forecasting

REPORT OBJECTIVES & Highlight

Report Description According to the latest report by IMARC Group, titled "Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," the global hyperlipidemia drugs market grew at a CAGR of around 3% during 2014-2019. Hyperlipidemia is a lipid disorder that is caused due to the elevation of fat levels in the bloodstream of an individual. Commonly referred to as high cholesterol, it is caused due to a disorder in the synthesis as well as degradation of plasma lipoproteins. It can also be caused by improper lipid metabolism that can further lead to the development of numerous medical ailments, including obesity, diabetes, stroke, hypertension and cardiovascular diseases.

While the primary form of hyperlipidemia is caused by genetic factors, secondary hyperlipidemia is induced by environmental influences. Several medications, such as statins, PCSK9 inhibitors and miscellaneous antihyperlipidemic agents, are widely being prescribed by healthcare professionals to maintain the cholesterol production levels in the liver.

Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsample Market Trends: The market is primarily driven by the increasing number of cases of hyperlipidemia on the global level. This can be accredited to the changing lifestyle patterns of the masses and their shifting dietary preferences. The increasing prevalence of the medical condition can also be attributed to the lack of exercise among individuals and the rising number of smokers across the globe. This, coupled with the escalating cases of obesity cases among the masses, is providing a thrust to the sales of hyperlipidemia drugs. There has also been a considerable rise in the geriatric population, which is susceptible to develop cardiovascular diseases and usually have high levels of cholesterol. This is acting as another major growth-inducing factor. Additionally, increasing awareness regarding the numerous treatment options available for combating hyperlipidemia is

Report Description which will facilitate the uptake of these drugs. Some of the other factors contributing to the market growth include growing investments in the healthcare sector, development of the overall infrastructure and the increasing research and development (R&D) activities for developing innovative drugs. Looking forward, IMARC Group expects the global hyperlipidemia drugs market to exhibit moderate growth during the next five years Hyperlipidemia Drugs Market Segmentation and Analysis of Top Key players: Historical, Current and Future Market Trends •

Breakup by Drug Type

1 Statins

2 Bile Acid Sequestrants q

3 Cholesterol Absorption Inhibitors

4 PCSK9 Inhibitors 5 Fibric Acid Derivatives 6 Others

Report Description

• Breakup by End User

•

• •

1 Hospitals 2 Clinics 3 Others Market Breakup by Region

1 North America 2 Asia Pacific 3 Europe 4 Latin America 5 Middle East and Africa

Competitive Landscape

1 Market Structure 2 Key Players 3 Profiles of Key Players

For more information about this report visit: https://www.imarcgroup.com/hyperlipidemia-drugs-market

Report Description Key Questions Answered in This Report: • How has the global hyperlipidemia drugs market performed so far and how will it perform in the coming years?

• What has been the impact of COVID-19 on the global hyperlipidemia drugs market?

• What are the key regional markets?

• What is the breakup of the market based on the drug type?

• What is the breakup of the market based on the end user?

• What are the various stages in the value chain of the industry?

• What are the key driving factors and challenges in the industry?

• What is the structure of the global hyperlipidemia drugs market and who are the key players?

• What is the degree of competition in the industry?

Table of Contents

Table of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Hyperlipidemia Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Drug Type 6.1 Statins 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Bile Acid Sequestrants 6.2.1 Market Trends

Table of Contents 6.2.2 Market Forecast 6.3 Cholesterol Absorption Inhibitors 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 PCSK9 Inhibitors 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Others 6.5.1 Market Trends 6.5.2 Market Forecast 7 Market Breakup by End User 7.1 Hospitals 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Clinics 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast

Table of Contents 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe

Table of Contents 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico

Table of Contents 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure

Table of Contents 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Amgen Inc. 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 AstraZeneca Plc 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 Daiichi Sankyo Company Limited 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 Financials 13.3.3.4 SWOT Analysis 13.3.4 Eli Lilly and Company 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 Esperion Therapeutics Inc. 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials

Table of Contents 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc) 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.6.4 SWOT Analysis 13.3.7 Immuron Limited 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.8 Ionis Pharmaceuticals Inc. 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.8.4 SWOT Analysis 13.3.9 Merck & Co. Inc. 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 Pfizer Inc. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis 13.3.11 Sanofi S.A.

Table of Contents 13.3.11.1 Company Overview 13.3.11.2 Product Portfolio 13.3.11.3 Financials 13.3.11.4 SWOT Analysis

Report FAQs Team Team Profile Profile

Team Profile

Engineers and Post Graduates Account for 75% of our Team

Growing team of 150+ employees with deep market knowledge

Over 1000 Independent Consultants from different sectors

Post Graduates; 30.00%

Engineers; 45.00%

Non Engineering Graduates; 15.00% Others; 10.00%

Talents from some of the top universities

modelling specialists with unmatched expertise in quantitative research Individuals with experience in specific industries and having sound knowledge of targeted functional areas Commercial and non-commercial relationships with some of the top research institutes

Report FAQs Words From Client

Words From Client

“We have been working with IMARC Group for over two years now. I must say that the word impossible doesn’t seems to appear in their dictionary,. These guys can provide data for any market in any country. I have been given them challenging assignments to work upon and have been quite impressed with their approach and results.”

-Global Procurement Technology Manager – Global FMCG Giant “IMARC Group has great domain expertise and knowledge base provided all the inputs necessary for us to define the path forward and launch our diagnostic successfully in the market where other players were always afraid before investing.”

-Vice President Marketing – European Diagnostic Company

“We were really impressed with their research findings on the South India dairy market. The innovative idea suggested by them have given us altogether different aspect to look at the problem. We started with them on small project but now thinking on doing more strategic project with them.”

-National Manager (Marketing) – Indian Diary Giant “IMARC Group helped us with the outsourcing of a major part of clinical trials to India. In the beginning we were skeptic of this idea. But the success achieved from this strategy is driving us to outsource other verticals of our business to low cost destinations” - Member of Board of Managing Director – Global Pharmaceutical Giant “Working with IMARC Group has been a great experience. They were able to provide us with a comprehensive business report on the India wastewater treatment market. The finding from the reports are played a major role in our business strategies and future decision making” -Senior Vice President – Major Indian Effluent Treatment Company

Report FAQs

Report FAQs

Report FAQs

01 02 03 04 05

Do you provide market share information for a specific country/segment?

Yes, we provide market share information and insights considering the scope. This service is provided as a part of customization requirements.

My research requirement is very specific; can I customized the report?

Yes, we provide customization of reports based on your requirements. It will be charged based on the scope of customization. Client have free access to pre-sales analyst briefs to discuss requirement and recommendations.

How do you arrive at the market numbers?

Our research methodology is a three cyclic process. It starts from information procurement from our inhouse database, primary research and secondary sources. The second step is data collection and analysis.

The third step is data validation from industry experts, key players and other stakeholders.

I have a pre-defined budget. Can I buy chapters/sections of the report?

We generally do not promote the sale of separate or individual segments from within a study, as it might fail to relay the actual meaning of the study or provide a holistic picture of the market. However, in special cases, select chapters are provided based on the client requirement.

Do you offer post sales support?

Yes, we offer post purchase analyst support for 4-6 weeks to our client in case they have any query within the scope of study.

Report FAQs

06 07 08 09

Who are your client?

We have engaged 550+ clients across the globe. More than half of our client are re-engage us for additional reports and services

How will I receive the report?

The report in a PDF and Excel format will be sent to you electronically at your registered email address.

Moreover, PPT and Word formats are also delivered to clients, on special requests.

How often does IMARC update studies?

Research studies or reports are updated once in 6 months or a year depending on the traction & need. Please contact our sales team to inquire about a report update status.

Will I have to pay for the post-sale customization needs?

We offer our clients with a free 10% customization on the syndicated report. In case you have not availed this service as a pre-sale facility, we request you to share the requirements with our sales team. The research team post a feasibility will share the purview of the post-sale customization along with the price (if applicable) and the timeline.

SOME OF OUR KEY CUSTOMERS